Prime Editing Creates Drug-Controllable T Cell Therapies

• October 28, 2026

Diagnostic performance and pathologic associations of the UroVysion assay in patients with upper tract lesions and negative urinary cytology: a large-scale real-world study of 1,256 patients

• by Longtao Zheng, Bao Guan, Zheng Wu, Yi Ding, Bei Zhang, Xuesong Li, Yanqing Gong

• October 18, 2026

Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

• by Jesús Duque-Afonso, Jürgen Finke, Allain-Thibeault Ferhat, Jacques-Emmanuel Galimard, Francesca Kinsella, Deborah Richardson, Friedrich Stölzel, Eleni Tholouli, Caroline Besley, Matthias Eder, Emma Nicholson, Robert Zeiser, Adrian Bloor, Charles Crawley, Katherine Clesham, Jennifer Byrne, Patrick Medd, Elisa Sala, Caroline Pabst, Jan Vydra, Eva Maria Wagner-Drouet, Alain Gadisseur, Alexandros Spyridonidis, Eolia Brissot, Arnon Nagler, Mohamad Mohty, Fabio Ciceri

• October 23, 2026

Musings from The Power List: Piers Ingram

Piers Ingram discusses the resurgence of immunology, engineering-led drug discovery, and how artificial intelligence can shape the next generation of medicines

• October 20, 2026

• 5 min